Ansbert Gadicke Sells 83,230 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 83,230 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $0.97, for a total value of $80,733.10. Following the transaction, the insider owned 4,784,111 shares in the company, valued at $4,640,587.67. This represents a 1.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Wednesday, December 3rd, Ansbert Gadicke sold 57,225 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total value of $49,785.75.
• On Tuesday, December 2nd, Ansbert Gadicke sold 59,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $52,756.53.
• On Monday, December 1st, Ansbert Gadicke sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $57,261.98.
• On Friday, November 28th, Ansbert Gadicke sold 20,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $20,074.23.
• On Wednesday, November 26th, Ansbert Gadicke sold 60,733 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $59,518.34.
• On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.92, for a total transaction of $39,130.36.
• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $87,025.96.
• On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.

Werewolf Therapeutics Price Performance

NASDAQ HOWL traded up $0.08 during trading on Thursday, reaching $1.00. 587,802 shares of the company traded hands, compared to its average volume of 504,491. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The stock’s 50 day moving average price is $1.42 and its two-hundred day moving average price is $1.33. The company has a market cap of $48.36 million, a price-to-earnings ratio of -0.61 and a beta of 0.74. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analyst Weigh In

HOWL has been the subject of a number of analyst reports. Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. JMP Securities cut their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Bank of America dropped their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Finally, Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.75.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HOWL. Charles Schwab Investment Management Inc. increased its stake in shares of Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after buying an additional 23,852 shares during the period. MPM Asset Management LLC lifted its stake in shares of Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares during the period. MPM Bioimpact LLC boosted its holdings in Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares during the last quarter. Nuveen LLC acquired a new stake in Werewolf Therapeutics in the first quarter worth about $71,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter worth about $92,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.